Time to address price hikes in US generic drugs

By Ed Price

Posted: March 17, 2016

API Manufacturing and Pharmaceutical Manufacturing

Manufacturing Chemist – February 26, 2016

Generic drugs costs have climbed dramatically in recent years, hitting US patients and producers. Edward S. Price, PCI Synthesis, argues it’s time the increasing costs were addressed.

A brief excerpt is available on ManufacturingChemist.com. The full article is available ONLY to subscribers of Manufacturing Chemist. Subscribe now to Manufacturing Chemist.

Related posts:

Grading GDUFA
State Needs to Recognize Biotech Evolution
Biotech’s Riding the Polar Express
2015 Trends and Predictions for API Drug Manufacturing
Sourcing Raw Materials for Chemical Manufacturing

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.